October 1, 2023 - In a special feature by Drug Development and Delivery, Dr. Anquetil, PHD, MBA, CEO and Founder of Portal Instruments, explains how PRIME not only prioritizes patient comfort and compliance but also aligns with environmental sustainability.
Portal Instruments: PFS Addresses Variety of Injection Challenges
October 1, 2023 - Portal Instruments, led by Dr. Patrick Anquetil, PHD, MBA, CEO and Founder, is setting a new standard in drug delivery with its groundbreaking PRIME device. In a special feature, Dr. Anquetil explains how PRIME not only prioritizes patient comfort and compliance but also aligns with environmental sustainability. This needle-free injection device offers a revolutionary approach to high viscosity therapies, addressing challenges such as needle fear, injection pain, and the need for real-time tracking and reminders.
Read the full Drug Development and Delivery special feature here.
October 2024 - At the Partnership Opportunities in Drug Delivery (PODD) conference, Robert Hidalgo showcased Portal Instrument's latest advancements on its reusable, electro-mechanical drug delivery platform.
October 2019 - Drug development is a costly, long, and uncertain endeavor. The cost of taking a drug from preclinical research through market approval is $2.6 billion according to a recent study by the Tufts Center for the Study of Drug Development.
March 2021 - With the COVID-19 vaccine becoming more readily available, there is the outstanding question of how many people will get vaccinated and will it be enough to help society as a whole achieve herd immunity.
Please fill out the details below and we will get back to you shortly.